NO20071570L - Fremstilling av TNFR-Ig fusjonsprotein - Google Patents
Fremstilling av TNFR-Ig fusjonsproteinInfo
- Publication number
- NO20071570L NO20071570L NO20071570A NO20071570A NO20071570L NO 20071570 L NO20071570 L NO 20071570L NO 20071570 A NO20071570 A NO 20071570A NO 20071570 A NO20071570 A NO 20071570A NO 20071570 L NO20071570 L NO 20071570L
- Authority
- NO
- Norway
- Prior art keywords
- cumulative
- culture
- amino acid
- glutamine
- molar
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 230000001186 cumulative effect Effects 0.000 abstract 9
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 2
- 229960001230 asparagine Drugs 0.000 abstract 2
- 235000009582 asparagine Nutrition 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012136 culture method Methods 0.000 abstract 1
- 229910001410 inorganic ion Inorganic materials 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Et forbedret system for storskala-produksjon av et dimert fusjonsprotein bestående av den ekstracellulære ligand-bindende del av human (p75) tumornekrosefaktor-reseptor (TNFR) bundet til Fc-delen av IgGI i cellekultur, spesielt i media karakterisert ved én eller flere av: i) en kumulativ aminosyre-konsentrasjon større enn ca. 70 mM; ii) et molart kumulativ glutamin til kumulativ asparagin forhold på mindre enn ca. 2; iii) et molart kumulativ glutamin til kumulativ total aminosyre forhold på mindre enn ca. 0,2; iv) et molart kumulativt uorganisk ion til kumulativ total aminosyre forhold mellom ca. 0,4 til 1; eller v) en kombinert kumulativ glutamin- og kumulativ asparagin-konsentrasjon mellom ca. 16 og 36 mM er gitt. Anvendelse av et slikt system tillater høye nivåer av protein-produksjon og minker akkumulering av visse uønskede faktorer så som ammonium og/eller laktat. I tillegg er kulturmetoder omfattende et temperaturskift, typisk omfattende en reduksjon av temperatur når kulturen har nådd ca. 20-80% av den maksimale celletetthet, gitt. Alternativt eller i tillegg tilveiebringer foreliggende oppfinnelse metoder slik at, etter å ha nådd en topp, laktat- og/eller ammonium-nivåer i kulturen reduseres over tid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60537904P | 2004-08-27 | 2004-08-27 | |
PCT/US2005/030439 WO2006026447A2 (en) | 2004-08-27 | 2005-08-26 | PRODUCTION OF TNFR-Ig FUSION PROTEIN |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20071570L true NO20071570L (no) | 2007-05-23 |
NO344785B1 NO344785B1 (no) | 2020-04-27 |
Family
ID=35500648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20071570A NO344785B1 (no) | 2004-08-27 | 2007-03-26 | Metode for å produsere TNFR-Ig i en storskala-produksjon cellekultur. |
Country Status (38)
Country | Link |
---|---|
US (1) | US7300773B2 (no) |
EP (2) | EP1781802B1 (no) |
JP (3) | JP2008511330A (no) |
KR (1) | KR100988451B1 (no) |
CN (2) | CN102876761A (no) |
AR (2) | AR050537A1 (no) |
AT (2) | ATE446376T1 (no) |
AU (1) | AU2005280036B2 (no) |
BR (1) | BRPI0514694B8 (no) |
CA (1) | CA2578138C (no) |
CL (1) | CL2017000577A1 (no) |
CR (2) | CR8998A (no) |
CY (2) | CY1109721T1 (no) |
DE (2) | DE602005020076D1 (no) |
DK (2) | DK1781802T3 (no) |
EC (1) | ECSP077354A (no) |
EG (1) | EG26922A (no) |
ES (2) | ES2335518T3 (no) |
GT (2) | GT200500234A (no) |
HK (2) | HK1099941A1 (no) |
HN (1) | HN2005000485A (no) |
HR (2) | HRP20100011T1 (no) |
IL (1) | IL181588A (no) |
MX (1) | MX2007002381A (no) |
MY (1) | MY137803A (no) |
NO (1) | NO344785B1 (no) |
NZ (1) | NZ579208A (no) |
PE (2) | PE20100448A1 (no) |
PL (2) | PL1781802T3 (no) |
PT (2) | PT1781802E (no) |
RS (2) | RS51255B (no) |
RU (1) | RU2458988C2 (no) |
SI (2) | SI1992697T1 (no) |
SV (1) | SV2006002211A (no) |
TW (1) | TWI364458B (no) |
UA (1) | UA89383C2 (no) |
WO (1) | WO2006026447A2 (no) |
ZA (1) | ZA200701672B (no) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
DK3255141T3 (da) * | 2006-07-13 | 2022-01-31 | Wyeth Llc | Fremstilling af antistoffer med forbedret glycosyleringsmønster |
WO2008055260A2 (en) * | 2006-11-03 | 2008-05-08 | Wyeth | Glycolysis-inhibiting substances in cell culture |
TW200827445A (en) * | 2006-11-08 | 2008-07-01 | Wyeth Corp | Rationally designed media for cell culture |
PT2115126E (pt) | 2007-03-02 | 2015-08-24 | Wyeth Llc | Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos |
TW200902708A (en) | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
TWI601823B (zh) | 2007-04-26 | 2017-10-11 | Chugai Pharmaceutical Co Ltd | Cell culture methods using media containing high concentrations of amino acids |
JP5739324B2 (ja) * | 2008-04-17 | 2015-06-24 | ワイス・エルエルシー | 骨形成タンパク質の産生増進法 |
JP2011516086A (ja) * | 2008-04-18 | 2011-05-26 | 上海中信国健薬業股▲ふん▼有限公司 | 濃縮培養液及びその使用方法 |
WO2010016943A2 (en) * | 2008-08-08 | 2010-02-11 | Biogen Idec Ma Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
RU2639288C2 (ru) | 2009-08-11 | 2017-12-20 | Дженентек, Инк. | Получение белков в культуральных средах без глутамина |
BR112012013330A2 (pt) * | 2009-12-02 | 2017-03-28 | Acceleron Pharma Inc | composições e métodos para aumentar meia vida do soro de proteínas de fusão fc |
RU2577972C2 (ru) | 2010-04-26 | 2016-03-20 | Новартис Аг | Способ получения рекомбинантного полипептида |
CA2797140C (en) | 2010-04-26 | 2018-01-23 | Novartis Ag | Improved cell culture medium |
CA2807607A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
JP2014503495A (ja) * | 2010-11-15 | 2014-02-13 | バイオジェン アイデック インコーポレイテッド | 過負荷結合および溶出クロマトグラフィによる選択生成物アイソフォームの富化および濃縮 |
DK2702164T3 (en) | 2011-04-29 | 2016-02-01 | Biocon Res Ltd | METHOD FOR REDUCING heterogeneity OF ANTIBODIES AND METHOD OF PRODUCING THESE ANTIBODIES |
US8883982B2 (en) | 2011-06-08 | 2014-11-11 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
AU2012326171B2 (en) | 2011-10-18 | 2017-03-09 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
AU2012324495B2 (en) | 2011-10-21 | 2016-04-21 | Pfizer Inc. | Addition of iron to improve cell culture |
NZ629309A (en) * | 2012-02-22 | 2016-03-31 | Nvip Pty Ltd | Tumour necrosis factor receptor fusion proteins and methods of using the same |
CA2878508A1 (en) | 2012-07-09 | 2014-01-16 | Coherus Biosciences, Inc. | Etanercept formulations exhibiting marked reduction in sub-visible particles |
EA031324B1 (ru) | 2012-09-11 | 2018-12-28 | Кохерус Байосайенсис, Инк. | Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
SG10201802023RA (en) | 2013-03-26 | 2018-05-30 | Coherus Biosciences Inc | Protein production method |
KR101439195B1 (ko) | 2013-04-18 | 2014-09-12 | 동아대학교 산학협력단 | 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정 |
US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
CN105637085A (zh) * | 2013-10-11 | 2016-06-01 | 瑞泽恩制药公司 | 代谢优化的细胞培养物 |
MX362923B (es) | 2014-01-30 | 2019-02-25 | Coherus Biosciences Inc | Medios de perfusión. |
KR20230136616A (ko) | 2014-02-04 | 2023-09-26 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온교환 크로마토그래피의 용도 |
EA036178B1 (ru) | 2014-12-01 | 2020-10-09 | Эмджен Инк. | Процесс контроля уровня содержания гликанов в составе гликопротеинов |
KR102007930B1 (ko) | 2014-12-31 | 2019-08-06 | 주식회사 엘지화학 | 재조합 당단백질의 글리코실화 조절 방법 |
CN105777897A (zh) * | 2015-03-20 | 2016-07-20 | 广东东阳光药业有限公司 | 一种cho细胞收获液的前处理方法 |
CN114807010A (zh) * | 2015-04-01 | 2022-07-29 | 勃林格殷格翰国际公司 | 细胞培养基 |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
EA201990998A1 (ru) | 2016-10-21 | 2019-11-29 | Фармацевтические составы и способы их получения | |
CN110484487A (zh) * | 2019-08-21 | 2019-11-22 | 安徽欣乐生物技术有限公司 | 一种适用于cho细胞培养用无蛋白培养基及其培养方法 |
US20240083972A1 (en) | 2020-12-22 | 2024-03-14 | Amgen Inc. | Cell culture method |
CN115073607A (zh) * | 2021-03-12 | 2022-09-20 | 上海康岱生物医药技术股份有限公司 | Tnfr2与baff受体的融合蛋白 |
CN114480492B (zh) * | 2022-01-28 | 2023-04-21 | 景泽生物医药(合肥)股份有限公司 | 一种重组人抗体融合蛋白的制备方法 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU632065B2 (en) * | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
US6048728A (en) * | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US6291159B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US5395760A (en) * | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
DE69032483T2 (de) * | 1989-10-05 | 1998-11-26 | Optein, Inc., Seattle, Wash. | Zellfreie synthese und isolierung von genen und polypeptiden |
US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5156964A (en) * | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
GB9118664D0 (en) * | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片 |
US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US20020012991A1 (en) | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
EP1385545B1 (en) | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
US7320790B2 (en) | 2001-04-30 | 2008-01-22 | Eli Lilly And Company | Humanized antibodies |
JP2004532642A (ja) | 2001-06-13 | 2004-10-28 | ジェネンテック・インコーポレーテッド | 動物細胞の培養方法と動物細胞でのポリペプチド産生 |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
JP4429728B2 (ja) | 2002-02-21 | 2010-03-10 | ワイス エルエルシー | フォリスタチン(follistatin)ドメイン含有タンパク質 |
AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DK1507556T3 (en) | 2002-05-02 | 2016-09-12 | Wyeth Holdings Llc | Calicheamicin derivative-carrier conjugates |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
-
2005
- 2005-08-25 TW TW094129077A patent/TWI364458B/zh not_active IP Right Cessation
- 2005-08-25 US US11/213,633 patent/US7300773B2/en active Active
- 2005-08-26 UA UAA200703287A patent/UA89383C2/ru unknown
- 2005-08-26 PL PL05791482T patent/PL1781802T3/pl unknown
- 2005-08-26 PE PE2009001227A patent/PE20100448A1/es active IP Right Grant
- 2005-08-26 AR ARP050103596A patent/AR050537A1/es not_active Application Discontinuation
- 2005-08-26 AU AU2005280036A patent/AU2005280036B2/en active Active
- 2005-08-26 PE PE2005000987A patent/PE20060815A1/es not_active Application Discontinuation
- 2005-08-26 SV SV2005002211A patent/SV2006002211A/es unknown
- 2005-08-26 NZ NZ579208A patent/NZ579208A/en not_active IP Right Cessation
- 2005-08-26 PT PT05791482T patent/PT1781802E/pt unknown
- 2005-08-26 CA CA2578138A patent/CA2578138C/en active Active
- 2005-08-26 HN HN2005000485A patent/HN2005000485A/es unknown
- 2005-08-26 ES ES05791482T patent/ES2335518T3/es active Active
- 2005-08-26 EP EP05791482A patent/EP1781802B1/en not_active Revoked
- 2005-08-26 SI SI200530984T patent/SI1992697T1/sl unknown
- 2005-08-26 MX MX2007002381A patent/MX2007002381A/es active IP Right Grant
- 2005-08-26 PL PL08005732T patent/PL1992697T3/pl unknown
- 2005-08-26 DE DE602005020076T patent/DE602005020076D1/de active Active
- 2005-08-26 DE DE602005017285T patent/DE602005017285D1/de active Active
- 2005-08-26 AT AT05791482T patent/ATE446376T1/de active
- 2005-08-26 AT AT08005732T patent/ATE461285T1/de active
- 2005-08-26 WO PCT/US2005/030439 patent/WO2006026447A2/en active Application Filing
- 2005-08-26 RU RU2007108717/10A patent/RU2458988C2/ru active
- 2005-08-26 MY MYPI20054023A patent/MY137803A/en unknown
- 2005-08-26 SI SI200530874T patent/SI1781802T1/sl unknown
- 2005-08-26 CN CN2012102771283A patent/CN102876761A/zh active Pending
- 2005-08-26 BR BRPI0514694A patent/BRPI0514694B8/pt active IP Right Grant
- 2005-08-26 KR KR1020077004810A patent/KR100988451B1/ko active IP Right Grant
- 2005-08-26 CN CN2005800369388A patent/CN101061231B/zh not_active Expired - Fee Related
- 2005-08-26 PT PT08005732T patent/PT1992697E/pt unknown
- 2005-08-26 RS RSP-2010/0190A patent/RS51255B/sr unknown
- 2005-08-26 RS RSP-2009/0575A patent/RS51072B/sr unknown
- 2005-08-26 JP JP2007530167A patent/JP2008511330A/ja active Pending
- 2005-08-26 DK DK05791482.2T patent/DK1781802T3/da active
- 2005-08-26 ES ES08005732T patent/ES2341390T3/es active Active
- 2005-08-26 EP EP08005732A patent/EP1992697B1/en not_active Revoked
- 2005-08-26 GT GT200500234A patent/GT200500234A/es unknown
- 2005-08-26 GT GT200500233A patent/GT200500233A/es unknown
- 2005-08-26 DK DK08005732.6T patent/DK1992697T3/da active
-
2007
- 2007-02-26 ZA ZA2007/01672A patent/ZA200701672B/en unknown
- 2007-02-27 IL IL181588A patent/IL181588A/en unknown
- 2007-02-27 EG EGNA2007000222 patent/EG26922A/xx active
- 2007-03-16 CR CR8998A patent/CR8998A/es unknown
- 2007-03-26 NO NO20071570A patent/NO344785B1/no not_active IP Right Cessation
- 2007-03-27 EC EC2007007354A patent/ECSP077354A/es unknown
- 2007-07-16 HK HK07107585.9A patent/HK1099941A1/xx not_active IP Right Cessation
- 2007-07-16 HK HK09102060.2A patent/HK1121497A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 CY CY20101100022T patent/CY1109721T1/el unknown
- 2010-01-11 HR HR20100011T patent/HRP20100011T1/hr unknown
- 2010-05-14 HR HR20100271T patent/HRP20100271T1/hr unknown
- 2010-06-16 CY CY20101100556T patent/CY1110092T1/el unknown
-
2012
- 2012-02-17 JP JP2012033112A patent/JP5921910B2/ja active Active
- 2012-11-01 CR CR20120560A patent/CR20120560A/es unknown
- 2012-11-09 AR ARP120104234A patent/AR088824A2/es not_active Application Discontinuation
-
2016
- 2016-01-28 JP JP2016014650A patent/JP2016056214A/ja active Pending
-
2017
- 2017-03-09 CL CL2017000577A patent/CL2017000577A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071570L (no) | Fremstilling av TNFR-Ig fusjonsprotein | |
NO20071572L (no) | Fremstilling av polypeptider | |
MX2007002382A (es) | Producci??n de anticuerpos anti-amiloides beta. | |
IL292650B2 (en) | IL13RA2-targeted chimeric antigen receptor T cells | |
BR112017013189B1 (pt) | Agentes agonísticos de ligação ao receptor de tnf | |
CN107208069A (zh) | 用于表达免疫检查点调节因子的溶瘤病毒 | |
RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
KR20200044138A (ko) | 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도 | |
RU2010120677A (ru) | Клетка для получения гетеропротеинов и способ получения на ее основе | |
NO20076391L (no) | Sammensetninger og metoder for behandling av tilstander relatert til efrinsignaler med cupredoxin | |
NZ593893A (en) | Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases | |
JP2020512284A5 (no) | ||
MX2020012499A (es) | Compuestos heterocondensados de piridonas y su uso como inhibidores de la idh. | |
EP2530090A3 (en) | Anti-IL-13R alpha 1 antibodies and their uses thereof | |
EP2124522A4 (en) | PUTATIVE RECEPTOR OF CYTOKININ AND METHODS OF USE | |
RU2009117253A (ru) | Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании | |
CA2538863A1 (en) | Selection system containing non-antibiotic resistance selection marker | |
Wang et al. | The cloning and expression of renalase and the preparation of its monoclonal antibody | |
EA200700990A1 (ru) | Новые пептиды, которые связывают рецептор эритропоэтина | |
AU2013251375B2 (en) | Vascular endothelial growth factor antagonists and methods for their use | |
CN103421749B (zh) | 棉花多胺氧化酶GhPAO2基因及其应用 | |
WO2010005227A3 (ko) | 동물세포용 재조합 발현벡터 | |
CA3200980A1 (en) | Cytosolic protein targeting engineered deubiquitinases and methods of use thereof | |
Usami et al. | GENOME-WIDE ASSOCIATION STUDY IDENTIFIES NEW SUSCEPTIBILITY LOCI FOR UROLITHIASIS | |
Khandrika et al. | IN VIVO ACTIVATION OF P38 MITOGEN ACTIVATED PROTEIN KINASE SIGNALING CASCADE IN A HYPEROXALURIC RAT MODEL |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: PFIZER IRELAND PHARMACEUTICALS |
|
MM1K | Lapsed by not paying the annual fees |